<?xml version='1.0' encoding='utf-8'?>
<document id="20045016"><sentence text="Drug interactions evaluation: an integrated part of risk assessment of therapeutics." /><sentence text="Pharmacokinetic drug interactions can lead to serious adverse events or decreased drug efficacy" /><sentence text=" The evaluation of a new molecular entity's (NME's) drug-drug interaction potential is an integral part of risk assessment during drug development and regulatory review" /><sentence text=" Alteration of activities of enzymes or transporters involved in the absorption, distribution, metabolism, or excretion of a new molecular entity by concomitant drugs may alter drug exposure, which can impact response (safety or efficacy)" /><sentence text=" The recent Food and Drug Administration (FDA) draft drug interaction guidance (http://www" /><sentence text="fda" /><sentence text="gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101" /><sentence text="pdf) highlights the methodologies and criteria that may be used to guide drug interaction evaluation by industry and regulatory agencies and to construct informative labeling for health practitioner and patients" /><sentence text=" In addition, the Food and Drug Administration established a &quot;Drug Development and Drug Interactions&quot; website to provide up-to-date information regarding evaluation of drug interactions (http://www" /><sentence text="fda" /><sentence text="gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499" /><sentence text="htm)" /><sentence text=" This review summarizes key elements in the FDA drug interaction guidance and new scientific developments that can guide the evaluation of drug-drug interactions during the drug development process" /><sentence text="" /></document>